SunTrust Banks Equities Analysts Decrease Earnings Estimates for VERONA PHARMA P/S (NASDAQ:VRNA)
VERONA PHARMA P/S (NASDAQ:VRNA) – SunTrust Banks dropped their FY2019 earnings per share (EPS) estimates for VERONA PHARMA P/S in a research report issued to clients and investors on Tuesday, November 5th. SunTrust Banks analyst J. Lee now expects that the company will earn ($3.37) per share for the year, down from their previous forecast of ($3.15). SunTrust Banks also issued estimates for VERONA PHARMA P/S’s Q4 2019 earnings at ($1.02) EPS, FY2020 earnings at ($2.51) EPS, FY2021 earnings at ($1.71) EPS and FY2022 earnings at ($1.37) EPS.
A number of other equities research analysts have also weighed in on VRNA. Wedbush reaffirmed a “buy” rating on shares of VERONA PHARMA P/S in a research report on Tuesday, October 15th. ValuEngine raised VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research raised VERONA PHARMA P/S from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Friday.
VERONA PHARMA P/S (NASDAQ:VRNA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.27).
A hedge fund recently raised its stake in VERONA PHARMA P/S stock. Wedbush Securities Inc. lifted its stake in VERONA PHARMA P/S (NASDAQ:VRNA) by 24.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,315 shares of the company’s stock after acquiring an additional 6,000 shares during the period. Wedbush Securities Inc. owned 0.23% of VERONA PHARMA P/S worth $139,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 56.03% of the company’s stock.
About VERONA PHARMA P/S
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
Featured Article: Municipal Bonds
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.